- Seda has established a new Swedish presence at Medicon Village in Lund, expanding its footprint in the Nordic life science sector.
- The site will serve as a base to strengthen regional partnerships and expand access to Seda’s expertise in pharmaceutical development, clinical pharmacology, and GMP manufacturing.
Seda has announced the establishment of a new Swedish presence at Medicon Village in Lund, one of Scandinavia’s life science hubs. The move marks an expansion of the company’s activities in the Nordic region.
Medicon Village hosts more than 2,800 researchers, entrepreneurs, and industry professionals across the life science value chain. Seda stated that the location positions the company within an ecosystem of research institutions, start-ups, and established companies, supporting collaboration and partnership development.
Helena Engman will serve as Seda’s main point of contact at the Lund site. She is Senior Principal Scientist, ADME Sciences, and holds a Master of Pharmacy and a PhD in Biopharmaceutics from the University of Uppsala, Sweden. With 21 years of experience in early- and late-stage drug product development, she provides scientific advice on clinical pharmacology, biopharmaceutics, and pharmacokinetic modeling for development and regulatory purposes.
“The Nordic countries possess a distinguished legacy of developing breakthrough medicines, underpinned by a strong commitment to scientific excellence that closely aligns with Seda’s philosophy. I am pleased that Helena, who exemplifies these values, will provide a local Swedish presence.”
Chief Scientist and Co-Founder Paul Dickinson
The new location will serve as a strategic base for strengthening relationships with Swedish and regional partners, supporting local initiatives, and expanding access to Seda’s expertise across pharmaceutical development, clinical pharmacology, and GMP manufacturing.
